N-Acetyl-L-tryptophan

Name: N-Acetyl-L-tryptophan
Brand: MedChemExpress
SKU: HY-W011978
Rating: 4.5 (1 reviews)

Cat. No.: HY-W011978 Purity: 99.38%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases.

For research use only. We do not sell to patients.

N-Acetyl-L-tryptophan Chemical Structure

CAS No. : 1218-34-4

Size	Price	Stock	Quantity
Free Sample (0.1 - 0.5 mg)		Apply Now
500 mg	USD 25	In-stock	Estimated Time of Arrival: December 31
1 g	USD 40	In-stock	Estimated Time of Arrival: December 31
5 g		Get quote
10 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of N-Acetyl-L-tryptophan:

N-Acetyl-L-tryptophan (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Neurokinin Receptor Isoform Specific Products:

View All Isoforms

NK1 NK2 NK3

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

NK1

Caspase-1

IL-1β

In Vitro

N-Acetyl-L-tryptophan (0.001–10 nM, 0.1–300 µM, 2 h) exhibits neuroprotective effects in a H₂O₂-induced amyotrophic lateral sclerosis model (cell lines: NSC-34 motoneurons and primary motor neurons.) induced by H₂O₂^[1].
N-Acetyl-L-tryptophan (30 μM, 15 min-6 h) inhibits the secretion of Substance P (HY-P0201) and lL-1β and the activation of caspase-1 in NSC-34 motoneurons^[1].
N-Acetyl-L-tryptophan (10 μM, 2 h) inhibits cell death in a H₂O₂-induced amyotrophic lateral sclerosis model by preventing the release of cytochrome c, Smac, and AIF from the mitochondria^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	H₂O₂-induced amyotrophic lateral sclerosis model (NSC-34 motoneurons and Primary motor neurons)
Concentration:	0.001, 0.01, 0.1, 1, 10 nM, 0.1, 1, 10, 30, 200, 300 μM
Incubation Time:	2 h
Result:	Significantly inhibited H₂O₂-induced cell death in NSC-34 motoneurons and primary motor neurons, with IC₅₀ values of 0.3 µM and 16 nM, respectively.

Western Blot Analysis^[1]

Cell Line:	H₂O₂-induced amyotrophic lateral sclerosis model (NSC-34 motoneurons)
Concentration:	10 μM
Incubation Time:	2 h
Result:	Effectively inhibited the release of cytochrome c/Smac/AIF from mitochondria into the cytoplasm.

In Vivo

N-Acetyl-L-tryptophan (10 mg/kg, i.p., single dose) confers hepatoprotection in an ischemia-reperfusion-induced Sprague-Dawley (SD) rat liver injury model by inhibiting excessive mitophagy^[3].
N-Acetyl-L-tryptophan (0.5 mg/kg, s.c., once daily for 21 days) reduces the incidence of L-DOPA (HY-N0304)-induced dyskinesia (LID) in the hemi-parkinsonian rodent model (Sprague-Dawley rats)^[3].
N-Acetyl-L-tryptophan (50 mg/kg, i.p., once daily for 28 days) can improve spatial memory deficits in the AlCl₃-induced Wistar rat dementia model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ischemia-reperfusion-induced liver injury model in Sprague-Dawley (SD) rats (200-220 g)^[2]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection (i.p.), single dose
Result:	Reduced the expression of autophagy markers (Beclin1, LC3-II, ATG-7, and P62) in the ischemia-reperfusion-induced Sprague-Dawley (SD) rat liver injury model.

Animal Model:	L-DOPA (HY-N0304)-induced abnormal involuntary movements model in Spraguee Dawley rats(230-270 g, before L-DOPA induction, a hemi-parkinsonian model was created by Oxidopamine hydrobromide (HY-B1081A))
Dosage:	0.5 mg/kg
Administration:	Subcutaneous injection (s.c.), once daily for 21 days
Result:	Significantly reduced the onset of dyskinesia.

Molecular Weight

246.26

Formula

C₁₃H₁₄N₂O₃

CAS No.

1218-34-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (406.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0607 mL	20.3037 mL	40.6075 mL
5 mM	0.8121 mL	4.0607 mL	8.1215 mL
10 mM	0.4061 mL	2.0304 mL	4.0607 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.38%

Select Batch:

Data Sheet (284 KB) SDS (393 KB)

COA (255 KB) HNMR (119 KB) RP-HPLC (281 KB)

Handling Instructions (2659 KB)

References

[1]. Sirianni A C, et al. N‐acetyl‐l‐tryptophan, but not N‐acetyl‐d‐tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis[J]. Journal of Neurochemistry, 2015, 134(5): 956-968. [Content Brief]

[2]. Li H, et al. Inhibition of excessive mitophagy by N-acetyl-L-tryptophan confers hepatoprotection against Ischemia-Reperfusion injury in rats[J]. PeerJ, 2020, 8: e8665. [Content Brief]

[3]. Thornton E, et al. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model[J]. Parkinsonism & related disorders, 2014, 20(5): 508-513. [Content Brief]

[4]. Fernandes J, et al. N-acetyl-L-tryptophan, a substance-P receptor antagonist attenuates aluminum-induced spatial memory deficit in rats[J]. Toxicology Mechanisms and Methods, 2018, 28(5): 328-334. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.0607 mL	20.3037 mL	40.6075 mL	101.5187 mL
	5 mM	0.8121 mL	4.0607 mL	8.1215 mL	20.3037 mL
	10 mM	0.4061 mL	2.0304 mL	4.0607 mL	10.1519 mL
	15 mM	0.2707 mL	1.3536 mL	2.7072 mL	6.7679 mL
	20 mM	0.2030 mL	1.0152 mL	2.0304 mL	5.0759 mL
	25 mM	0.1624 mL	0.8121 mL	1.6243 mL	4.0607 mL
	30 mM	0.1354 mL	0.6768 mL	1.3536 mL	3.3840 mL
	40 mM	0.1015 mL	0.5076 mL	1.0152 mL	2.5380 mL
	50 mM	0.0812 mL	0.4061 mL	0.8121 mL	2.0304 mL
	60 mM	0.0677 mL	0.3384 mL	0.6768 mL	1.6920 mL
	80 mM	0.0508 mL	0.2538 mL	0.5076 mL	1.2690 mL
	100 mM	0.0406 mL	0.2030 mL	0.4061 mL	1.0152 mL